Discovery and Development

What has led to the rising trend for Cell & Gene Therapy (CGT) developers to choose retroviral vectors over other potential vectors, and what are the many drivers behind this selection process?

IPT talks to Dr Fiona McLaughlin and Neil Bell of Avacta Therapeutics about the need for cohesion when researching and developing a new drug between life science companies, academia, and medical practitioners

IPT talks to Johannes Stanta at Celerion about how improvements in molecular and cellular capabilities are aiding Good Laboratory Practice/Good Clinical Practice (GLP/GCP) standards

The in vitro-in silico ‘alternative’ bioequivalence pathway for generic inhaled drug products, and how to factor in patient variability to successfully replace your comparative clinical end-point study

From tools and assays, to the need for improved collaboration, the potential answers to this question are numerous. IPT asked representatives from DeciBio, Cybin, and GORE PharmBIO for their opinions

Michael Avraam at ChargePoint Technology walks IPT through the challenges and obstacles that companies face when looking to build safety, quality, and efficiency into their potent active pharmaceutical ingredient (API) processes

Pharma has been slow to adopt new technology in its manufacturing plants, partly because it fears change and partly because it often has a mix of legacy equipment. However, embracing greater interoperability through technology can smooth processes and support data integrity.